Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728589 | 1.00 | CXCR3 (0.65) | CXCR3KCNH2POLBALDH1A1PDE4B | |
| SCHEMBL113584 | 0.95 | CXCR3 (0.67) | CXCR3KCNH2POLBALDH1A1PDE4B | |
| SCHEMBL3729670 | 0.89 | CXCR3 (0.68) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL3735474 | 0.88 | CXCR3 (0.70) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL3735480 | 0.88 | CXCR3 (0.70) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL3732644 | 0.87 | CXCR3 (0.65) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL3726265 | 0.85 | CXCR3 (0.65) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL3728431 | 0.85 | CXCR3 (0.75) | CXCR3KCNH2POLBALDH1A1LMNA | |
| SCHEMBL114619 | 0.85 | CXCR3 (0.67) | CXCR3KCNH2POLBALDH1A1PDE4B | |
| SCHEMBL3733677 | 0.85 | CXCR3 (0.67) | CXCR3KCNH2POLBALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | claimed |
| EP-2424840-B1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8450317-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280028-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 1561/4885POLB 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.